|
|
|
市場調查報告書
ADME－毒性檢査市場
ADME-Toxicology Testing
|
ADME－毒性檢査市場 是由出版商Global Industry Analysts, Inc.在2011年08月所出版的。
這份英文市場調查報告書包含Pages: 572 價格從美金4500起跳。
本報告書為全球ADME毒性檢査市場的相關調査分析、ADME／毒性市場動向、創藥與藥劑開發動向、產品概要、產品上市動向等概說，同時包含全球主要各地區的動向、以及相關企業的簡介統整，概述如下。
第1章 導論、調査方法、產品定義
第2章 業界概要
- ADME：勢力增加的毒性檢査
- 現狀與將來分析
- 以將醫藥品業界的再編成做成本最家化為中心
- 中國與印度：研究開發投資的中心地
- CRO的存在擴大
- 合作必要性的擴大
第3章 市場動向
- 形成ADME／毒性市場的動向與技術
- 針對毒性研究的體外測定動向
- 革新的方法
- 比其他毒性試驗方法，細胞檢測更常被使用
- 機能性測試：預測特定的毒性高價之有效方法
- 早期體外ADMET研究摘要
- 創藥之幹細胞
- 初代肝細胞成為肝代謝之評價標準工具
- 為了促進體外毒性測試的3D組織生物檢驗
- In Silico ADME毒性測試
- 心毒性檢査
- 電腦模型登場
- 資料管理系統的導入
- 藥劑輸送分析成為ADME評價的一部分
第4章 創藥與藥劑開發
- 創藥與藥劑開發
- 標的鎖定
- 標的驗證
- 讀取鑑定
- 讀取最佳化
- 前臨床測試
- 臨床測試
- 創藥技術
- 監測技術革新保證創藥過程的成功
第5章 產品概要
- ADME：導論
- 毒性檔案建立
- 毒性監測技術
- 毒性參數
- 細胞檢測
第6章 產品上市／技術革新／法規體制承認
第7章 近年業界活動
第8章 主要企業
- Accelrys, Inc.
- ACEA Biosciences, Inc.
- Agilent Technologies, Inc
- Albany Molecular Research, Inc.
- Aureus Sciences
- Bayer Technology Services GmbH
- BD Bioscience
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc.
- Caliper Life Sciences, Inc.
- Cambridge Cell Networks Ltd.
- CeeTox, Inc.
- Cellartis AB
- Celsis International Ltd.
- Cerep SA
- CompuDrug International, Inc.
- Cyprotex PLC.
- Entelos, Inc.
- Galapagos NV
第9章 世界市場前景
第10章 美國
第11章 加拿大
第12章 日本
第13章 歐洲
第14章 其他地區
企業簡介：83家
Abstract
This report analyzes the worldwide markets for ADME-Toxicology Testing in US$ Million by the following Product Segments: Toxicology Testing (In-Vivo, & In-Vitro), and ADME Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 83 companies including many key and niche players such as Accelrys, Inc., ACEA Biosciences, Inc., Agilent Technologies, Inc., Albany Molecular Research, Inc., Aureus Sciences, Bayer Technology Services GmbH, BD Biosciences, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Inc., Cambridge Cell Networks Ltd., CeeTox, Inc., Cellartis AB, Celsis International Ltd., Cerep SA, CompuDrug International, Inc., Cyprotex PLC, Entelos, Inc., Galapagos NV, Life Technologies Corporation, Molecular Discovery Ltd., MultiCASE, Inc., Noray Bioinformatics S.L., 0ptivia Biotechnology, Pharmacon, Inc., Promega Corporation, Qualyst, Inc., Simulations PIus, Inc., Sirius analytical Instruments Ltd., Taconic Farms, Inc., Tecan Group Ltd., Thermo Fisher Scientific, Inc., and Xceleron, Inc. Market data and analytics are derived from primary and secondary research. Company proflIes are mostly extracted from URL research and reported select online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- ADME-Tox - An Introduction
- Toxicology Testing
- ADME Testing
- Absorption
- Distribution
- Metabolism
- Excretion
2. INDUSTRY OVERVIEW
- ADME-Tox Testing Gains Traction
- Table 1: Leading Causes of Failure During New Drug Development:
Percentage Share Breakdown by ADME/Tox Issues, Insufficient Efficacy,
Adverse Side Effects, and Commercial Viability (includes corresponding
Graph/Chart)
- Current and Future Analysis
- Pharma Industry Renews Focus on Cost Optimization
- Table 2: US R&D Productivity Trends in Pharma Industry (2000-
2010) (includes corresponding Graph/Chart)
- China and India: Hot Spots for R&D Investment
- Table 3: Percentage Breakup of Global R&D Spending by Region
(2009) (includes corresponding Graph/Chart)
- CROs Expand Presence
- Growing Need for Collaborations
3. MARKET DYNAMICS
- Trends and Technologies Shaping the ADME/Tox Market
- Growing Inclination Towards In-vitro Assays for Toxicology Studies
- Focus Shifts to Innovative Approaches
- Increasing Use of Cell-Based Assays over Other Methods in Toxicity
Testing
- Functional Assays: An Effective Way of Predicting Specific Toxic Effects
- Introduction of Early In Vitro ADMET Studies
- Stem Cells in Drug Discovery
- Primary Hepatocytes Become Standard Tool for Evaluation in Hepatic
Metabolism
- 3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing
- In Silico ADME-Tox Growing at a Fast Clip
- Factors Hindering Growth
- Cardiotoxicity Testing Gains Prominence
- Computational Models on Rise
- Adoption of Data Management Systems
- Drug Transporter Analysis Becoming Part of ADME Assessment
- Regulatory Bodies Focus on Transporter Mediated DDIs
4. DRUG DISCOVERY & DEVELOPMENT
- Table 4: Escalating Costs of New Drug Development Over the Decades
(includes corresponding Graph/Chart)
- Drug Discovery and Development
- Target identification
- Target Validation
- Lead Identification
- Lead Optimization
- Pre-Clinical Testing
- Clinical Trials
- Drug Discovery Technologies
- Innovation in Screening Guarantees Success for Drug Discovery Programs
5. PRODUCT OVERVIEW
- ADME-Tox - An Introduction
- Absorption
- Distribution
- Metabolism
- Excretion
- Toxicity
- ADME-Tox Profiling
- ADME-Tox Screening Technologies
- ADME-Tox Parameters
- Cell Based Assays
- Liver Cell Based Assays
- Intestinal Cell Based Assays
- Kidney Cell Based Assays
6. PRODUCT LAUNCHES/INNOVATIONS/ REGULATORY APPROVALS
- Simulations Plus to Develop Predictive QSAR Toxicity Models in
Partnership with FDA
- BIOCIUS Life Sciences Extends Contract Research Services Range,
Introduces New ADME Assay Analysis
- LGC Unveils reinnervate' s 3D Cell Culture Scaffold, Alvetex® for In
Vitro Toxicity Testing for Drug Discovery
- Cyprotex Unveils Cyprotox®, In Vitro Toxicology Services
- Absorption System Rolls Out Express Plus ADME Assays
- LGC Standards Unveils ADME Toxicology Guide for New Drug Discovery
- Absorption System Secures Patent for BCP Knockdown Cell Line in CellPort
Technologies Brand
- Cyprotex Relaunches CellCiphr™ Toxicity Panels
- Sigma® Life Science Launches New Models of Knockout Rats for ADME-Tox
Applications
- Hudson Robotics Unveils VaryScreen ADME-Tox Workstation
- Agilent Technologies Rolls Out RF360 High Resolution System for
High-Throughput Screening of In Vitro ADME Assays
- MultiCell Technologies Receives Patent for EA1C-35 and Fa2N-4
Immortalized Human Hepatocyte Cell Lines
- Cyprotex Unveils Web Portal for Providing Access to Drug Discovery
Services
- Applied Biosystems/MDS Analytical Technologies Launches
DiscoveryQuant™ Software
- BioTrove Releases RapidFire 300 System for High-Throughput Screening
- CXR Biosciences and Millipore Launch ToxReporter™
7. RECENT INDUSTRY ACTIVITY
- CIT and Stemina Ink Strategic Partnership Deal for Distribution of
Toxicity Assay and New Technology Development
- Hamner forms Research Initiative for Development of 3D Tissue Bioassays
for Toxicity Testing
- Aureus Pharma Becomes Aureus Sciences and Unveils Extensive Life Sciences
Application Web Portal
- CeeTox Purchases ADMETRx' s Assets
- Phytopharm to Receive Chemistry and ADME Services Support from O2h
- Life Technologies Inks Licensing Agreement with Biopredic International
for HepaRG® Cells
- O2h to Provide ADME Services to Sentinel Oncology
- Galapagos Takes Over Argenta Discovery, Becomes Leading Drug Discovery
Services Provider
- BioFocus to Offer ADME Services as Part of Extended Partnership Deal with
Chisei
- Cyprotex to Take Over Apredica and Cellumen
- Optivia and UCSF Receive SBIR Grant for Development of ADME Systems
- Accelrys Merges with Symyx
- Lonza Group Purchases Simbiosys Biowares India Pvt Ltd
- Gentronix and Apredica Collaborate for Predictive Toxicology Services
- AsisChem Joins Forces with Apredica for Drug Discovery Support Services
- Batelle Ventures Funds Hepregen' s Spin-Off from MIT
- ADMETRx and CeeTox Enter into Partnership to Provide Extensive ADME-Tox
Services
- Promega and Celsis IVT Ink Agreement to Collaborate for ADME-Tox Testing
in Primary Hepatocytes
- Pharma Algorithms and ACD/Labs Collaborate to Enhance In Silico
Prediction and Screening
8. FOCUS ON SELECT GLOBAL PLAYERS
- Accelrys, Inc. (US)
- ACEA Biosciences, Inc. (US)
- Agilent Technologies, Inc. (US)
- Albany Molecular Research, Inc. (US)
- Aureus Sciences (France)
- Bayer Technology Services GmbH (Germany)
- BD Biosciences (US)
- Beckman Coulter, Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- Caliper Life Sciences, Inc. (US)
- Cambridge Cell Networks Ltd. (UK)
- CeeTox, Inc. (US)
- Cellartis AB (Sweden)
- Celsis International Ltd. (US)
- Cerep SA (France)
- CompuDrug International, Inc. (US)
- Cyprotex PLC. (US)
- Entelos, Inc. (US)
- Galapagos NV (Belgium)
- Life Technologies Corporation (US)
- Molecular Discovery Ltd (UK)
- MultiCASE, Inc. (US)
- Noray Bioinformatics S.L. (Spain)
- Optivia Biotechnology
- Pharmaron, Inc. (US)
- Promega Corporation (US)
- Qualyst, Inc. (US)
- Simulations Plus, Inc. (US)
- Sirius Analytical Instruments Ltd (UK)
- Taconic Farms, Inc. (US)
- Tecan Group Ltd. (Switzerland)
- Thermo Fisher Scientific, Inc. (US)
- Xceleron, Inc. (UK)
9. GLOBAL MARKET PERSPECTIVE
- Table 5: World Recent Past, Current & Future Analysis for ADME -
Tox Testing by Geographic Region - US, Canada, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2008 Through 2017 (includes corresponding Graph/Chart)
- Table 6: World 10-Year Perspective for ADME - Tox Testing by Geographic
Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan,
Europe, and Rest of World Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
- Table 7: World Recent Past, Current & Future Analysis for
Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2008 Through 2017 (includes corresponding Graph/Chart)
- Table 8: World 10-Year Perspective for Toxicology Testing by Geographic
Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan,
Europe, and Rest of World Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
- Table 9: World Recent Past, Current & Future Analysis for
Toxicology Testing by Sub-Segment - In-Vivo and In-Vitro Testing Markets
Independently Analyzed with Annual Revenue Figures in US$ Million for Years
2008 Through 2017 (includes corresponding Graph/Chart)
- Table 10: World 10-Year Perspective for Toxicology Testing by
Sub-Segment - Percentage Breakdown of Dollar Revenues for In-Vivo and In-Vitro
Testing Markets for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart)
- Table 11: World Recent Past, Current & Future Analysis for In-Vivo
Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2008 Through 2017 (includes corresponding Graph/Chart)
- Table 12: World 10-Year Perspective for In-Vivo Toxicology Testing by
Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada,
Japan, Europe, and Rest of World Markets for Years 2008, 2011 & 2017
(includes corresponding Graph/Chart)
- Table 13: World Recent Past, Current & Future Analysis for In-Vitro
Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2008 Through 2017 (includes corresponding Graph/Chart)
- Table 14: World 10-Year Perspective for In-Vitro Toxicology Testing by
Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada,
Japan, Europe, and Rest of World Markets for Years 2008, 2011 & 2017
(includes corresponding Graph/Chart)
- Table 15: World Recent Past, Current & Future Analysis for ADME
Testing by Geographic Region - US, Canada, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in US$ Million for
Years 2008 Through 2017 (includes corresponding Graph/Chart)
- Table 16: World 10-Year Perspective for ADME Testing by Geographic
Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan,
Europe, and Rest of World Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
10. THE UNITED STATES
- A. Market Analysis
- Current and Future Analysis
- Clinical Trials Market in the US
- Product Launches/Regulatory Approvals
- Strategic Corporate Developments
- Select Players
- B. Market Analytics
- Table 17: US Recent Past, Current & Future Analysis for ADME -
Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Markets
Independently Analyzed with Annual Revenues in US$ Million for Years 2008
Through 2017 (includes corresponding Graph/Chart)
- Table 18: US 10-Year Perspective for ADME - Tox Testing by Segment -
Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo and
In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
11. CANADA
- A. Market Analysis
- Strategic Corporate Development
- B. Market Analytics
- Table 19: Canadian Recent Past, Current & Future Analysis for
ADME - Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME
Markets Independently Analyzed with Annual Revenues in US$ Million for Years
2008 Through 2017 (includes corresponding Graph/Chart)
- Table 20: Canadian 10-Year Perspective for ADME - Tox Testing by
Segment - Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo
and In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
12. JAPAN
- Market Analysis
- Table 21: Japanese Recent Past, Current & Future Analysis for
ADME - Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME
Markets Independently Analyzed with Annual Revenues in US$ Million for Years
2008 Through 2017 (includes corresponding Graph/Chart)
- Table 22: Japanese 10-Year Perspective for ADME - Tox Testing by
Segment - Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo
and In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
13. EUROPE
- A. Market Analysis
- Current and Future Analysis
- Clinical Trials Market in Europe
- Product Launches/Regulatory Approvals
- Strategic Corporate Developments
- Select Players
- B. Market Analytics
- Table 23: European Past, Current & Future Market Analysis for
ADME - Tox Testing by Country/Geographic Region - France, Germany, Italy,
UK, and Rest of Europe Markets Independently Analyzed with Annual Revenues
in US$ Million for Years 2008 through 2017 (includes corresponding
Graph/Chart)
- Table 24: European Recent Past, Current & Future Analysis for
ADME - Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME
Markets Independently Analyzed with Annual Revenues in US$ Million for Years
2008 Through 2017 (includes corresponding Graph/Chart)
- Table 25: European 10-Year Perspective for ADME - Tox Testing by
Country/Geographic Region - Percentage Breakdown of Dollar Sales for France,
Germany, Italy, UK, and Rest of Europe Markets for Years 2008, 2011 &
2017 (includes corresponding Graph/Chart)
- Table 26: European 10-Year Perspective for ADME - Tox Testing by
Segment - Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo
and In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
13a. FRANCE
- Market Analysis
- Table 27: France Recent Past, Current & Future Analysis for ADME
- Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME
Markets Independently Analyzed with Annual Revenues in US$ Million for Years
2008 Through 2017 (includes corresponding Graph/Chart)
- Table 28: French 10-Year Perspective for ADME - Tox Testing by
Segment - Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo
and In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
13b. GERMANY
- Market Analysis
- Table 29: German Recent Past, Current & Future Analysis for ADME
- Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME
Markets Independently Analyzed with Annual Revenues in US$ Million for Years
2008 Through 2017 includes corresponding Graph/Chart)
- Table 30: German 10-Year Perspective for ADME - Tox Testing by
Segment - Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo
and In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
13c. ITALY
- Market Analysis
- Table 31: Italian Recent Past, Current & Future Analysis for
ADME - Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME
Markets Independently Analyzed with Annual Revenues in US$ Million for Years
2008 Through 2017 (includes corresponding Graph/Chart)
- Table 32: Italian 10-Year Perspective for ADME - Tox Testing by
Segment - Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo
and In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
13d. THE UNITED KINGDOM
- Market Analysis
- Table 33: The UK Recent Past, Current & Future Analysis for ADME
- Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME
Markets Independently Analyzed with Annual Revenues in US$ Million for Years
2008 Through 2017 (includes corresponding Graph/Chart)
- Table 34: The UK 10-Year Perspective for ADME - Tox Testing by
Segment - Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo
and In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
13e. REST OF EUROPE
- A. Market Analysis
- Russia
- Table 35: Russian Clinical Trials Market (2009): Percentage
Breakdown by Trial Type - Global Multi- center Clinical Trials, Local
Clinical Trials (Foreign Sponsors), Local Clinical Trials (Local Sponsors),
Bioequivalence studies (Foreign Sponsors), and Bioequivalence Studies
(includes corresponding Graph/Chart)
- Table 36: Russian Clinical Trials Market (2008): Percentage
Breakdown by Hosting Countries - Russia, USA, Germany, UK, Switzerland, and
Others (includes corresponding Graph/Chart)
- Table 37: Number of Clinical Trials in Russia by Study Phase (2008)
(includes corresponding Graph/Chart)
- Spain
- Garnering Investments from Multinational Pharma Companies
- Phase III Clinical Trials Engross Maximum R&D Expenditure
- Table 38: Apportion of R & D Expenditure by Study Phase in
Spain: 2008 (includes corresponding Graph/Chart)
- B. Market Analytics
- Table 39: Rest of Europe Recent Past, Current & Future Analysis
for ADME - Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Markets Independently Analyzed with Annual Revenues in US$ Million for
Years 2008 Through 2017 (includes corresponding Graph/Chart)
- Table 40: Rest of Europe 10-Year Perspective for ADME - Tox Testing
by Segment - Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo
and In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
14. REST OF WORLD
- A. Market Analysis
- Current and Future Analysis
- Asia: The Most Preferred Destination for Clinical Trials
- India
- A Thriving Clinical Trials Market
- Table 41: Cost of Conducting Clinical Trials: India Vs. US (In US$
Million) (includes corresponding Graph/Chart)
- Latin America: An Emerging Market for Clinical Trials
- Table 42: Latin American Clinical Trials Market by Country (2009):
Percentage Share Breakdown for Brazil, Mexico, Argentina, Chile, Peru,
Colombia, Costa Rica, Guatemala, and Panama (includes corresponding
Graph/Chart)
- Strategic Corporate Development
- B. Market Analytics
- Table 43: Rest of World Recent Past, Current & Future Analysis
for ADME - Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro) and
ADME Markets Independently Analyzed with Annual Revenues in US$ Million for
Years 2008 Through 2017 (includes corresponding Graph/Chart)
- Table 44: Rest of World 10-Year Perspective for ADME - Tox Testing
by Segment - Percentage Breakdown of Dollar Revenues for Toxicology (In-Vivo
and In-Vitro) and ADME Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart)
COMPETITIVE LANDSCAPE
|
 |
